The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.75
Bid: 4.50
Ask: 5.00
Change: -0.10 (-2.06%)
Spread: 0.50 (11.111%)
Open: 4.75
High: 4.75
Low: 4.75
Prev. Close: 4.85
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EU registration milestone reached

17 Oct 2012 10:30

RNS Number : 8859O
Eden Research plc
17 October 2012
 



 

EDEN RESEARCH PLC

("Eden" or "Company")

  

EU registration milestone reached

 

Eden Research plc, the agrochemical and encapsulation development company, announces that the European Food Safety Authority ("EFSA") has concluded its review of the three active substance dossiers submitted by Eden for approval under Council Directive 91/414/EEC.

 

The review report will now be sent to the European Commission for their review before a vote by the EC member states will ultimately take place to approve the three active substances for use in plant protection products within the EU.

 

Clive Newitt, Managing Director of Eden said, "This is a significant milestone for Eden in a process which has taken a number of years and into which Eden has invested a considerable amount of time, money and effort. We are now at the tail end of the process and look forward to seeing it through to its conclusion which is expected to be in spring 2013, in line with previous announcements."

 

 

Eden Research plc

www.edenresearch.com

Clive Newitt, Managing Director

Tel: 01993 862 761

Alex Abrey, Chief Financial Officer

Zeus Capital Limited

Ross Andrews, Andrew Jones

(Nominated Advisor, Broker, Corporate Finance)

Tel: 0161 831 1512

John Goold (Institutional Sales)

 

Tel: 020 7106 8925

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus (Media Relations)

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Paul Cornelius (Investor Relations)

Mob: 07827 879 496 or paul.cornelius@walbrookir.com

 

Notes:

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

 

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

 

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

 

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

 

The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest (2010: £172,000; 2011: £91,000) whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

 

For more information about Eden, please visit www.edenresearch.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCMRBLTMBTBMLT
Date   Source Headline
24th Sep 20187:00 amRNSHalf-year Report
13th Jul 201810:23 amRNSDirector/PDMR Shareholding
21st Jun 20184:44 pmRNSResult of AGM
21st Jun 20187:00 amRNSAGM Statement
19th Jun 20187:00 amRNSDirector/PDMR Shareholding
14th Jun 20187:00 amRNSRegulatory Progress Update
30th May 20182:30 pmRNSPosting of Annual Report & Notice of AGM
10th May 20185:04 pmRNSDirector/PDMR Shareholding
8th May 20187:00 amRNSExercise of Options
20th Mar 20187:00 amRNSPreliminary results
11th Jan 20187:00 amRNSYear-end Trading Statement
12th Dec 20177:00 amRNSRegulatory Progress Update
29th Sep 201711:15 amRNSHalf-year Report - Replacement
29th Sep 20177:30 amRNSAdoption of New LTIP and Grant of Awards
29th Sep 20177:01 amRNSBoard Changes
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:00 amRNSApproval of MevaloneT in Portugal
1st Sep 20177:00 amRNSNotice of Results
30th Jun 20175:14 pmRNSHolding(s) in Company
30th Jun 201712:29 pmRNSResult of AGM
30th Jun 20177:43 amRNSAGM Statement
30th Jun 20177:39 amRNSCompletion of Placing & Subscription
30th Jun 20177:00 amRNSSipcam agreements, investment and proposed placing
29th Jun 20179:43 amRNSNew terms agreed with UMMS
5th Jun 20173:14 pmRNSPosting of Annual Report & Notice of AGM
22nd May 20177:00 amRNSFinal Results
11th May 20179:00 amRNSEden Research on BBC Radio 4's You & Yours
29th Mar 20177:00 amRNSExtension of patent protection in Greece
8th Mar 20172:40 pmRNSVoting Rights, Warrants and Options Outstanding
23rd Jan 20172:00 pmRNSPrice Monitoring Extension
23rd Jan 20177:00 amRNSFungicide product approved for sale in France
21st Dec 20167:01 amRNSTrading update
21st Dec 20167:00 amRNSEastman commercialisation agreement for nematicide
27th Sep 20167:00 amRNSHalf-year Report
28th Jun 201612:28 pmRNSResult of AGM
28th Jun 20167:00 amRNSAGM Statement
15th Jun 20167:00 amRNSLabel extensions for 3AEY in Spain and Greece
7th Jun 20167:00 amRNSPosting of Annual Report & Notice of AGM
26th May 20163:36 pmRNSDirector/PDMR Shareholding
24th May 20167:00 amRNSFinal Results
11th Apr 20169:31 amRNSHolding(s) in Company
30th Mar 20167:00 amRNSPlacing to raise £2.6m
22nd Feb 20167:00 amRNSApproval of 3AEY in Spain
11th Feb 20167:00 amRNSApproval of 3AEY in Italy
10th Feb 20167:00 amRNSFirst shipment of MevaloneT (3AEY) to Greece
21st Jan 20167:00 amRNSExercise of options
14th Jan 20167:00 amRNSFurther progress with EU product approvals
16th Nov 20157:00 amRNSKenya approval & first commercial-scale order
26th Oct 20157:00 amRNSAppointment of Nominated Adviser and Broker
24th Sep 20157:00 amRNSCollaboration and Licence Agreement Signed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.